

NEWS RELEASE

A Prospective, Randomised and Multicentre Trial Comparing Titan2 Bio Active Stent (BAS) and Xience V Drug Eluting Stent (DES): The BASE-ACS Trial.

AsiaPCR Sing LIVE 2012 Late Breaking Trial Session, Thursday, 12th January 2012, Main Arena
Chairpersons: J. Marco, T.H. Koh

Panellists: K.T Chan, T.Cuisset, D.S. Gambhir, N.A.M. Momenuzzaman, M.Munawar, C.K. Naber, D. Tresukosol, W.A. Wan Azman

The latest results of the multicenter prospective randomized controlled BASE-ACS trial have been presented at the occasion of the Late Breaking Trials during AsiaPCR/SingLIVE 2012, Thursday the 12th of January in Singapore by the Principal Investigator Pasi Karjalainen, MD, PhD, from the Heart Center, Satakunta Central Hospital, Pori, Finland.

This non-inferiority study which had already demonstrated the non-inferiority ($p=0.001$) of the Titanium-Nitride-Oxide coated stent versus the Everolimus eluting stent in ACS patients at a 12-month follow-up, enrolled 827 consecutive patients which received either a Titan2 Bio Active Stent (Hexacath, France) or a Xience V Active Stent (Abbott, USA).

The baseline patients, procedural and lesions characteristics were comparable in both groups. At 18 months, the cumulative incidence of MACE was 10.8% in the Titan2 group vs. 11.7% in the Xience V group ($p=0.74$). The rates of stent thrombosis and MI were significantly higher in the XienceV group (2.4% vs.0.7%, $p=0.047$) and (6.3% vs. 2.6%, $p=0.01$). The mean duration of clopidogrel was 8.7 months in the Titan2 group and 10.2 months in the Xience V group ($p<0.001$).

The BASE-ACS trial provides new additional data confirming the efficacy and safety of the Titan2 BAS in one of the highest risks patient population: NSTEMI and STEMI.

About Hexacath

Based in Rueil-Malmaison (Paris area), France, Hexacath is dedicated to the development, manufacture and distribution of innovative cardiovascular products to improve patients treatments. Hexacath has expanded its product portfolio with vascular stents made from nitinol and cobalt chromium platforms coated with its patented biological active coating titanium nitride oxide. During the last 16 years, Hexacath has opened direct subsidiaries in France, Spain, Italy, UK, Belgium, Sweden, Finland, India, China, Brazil, Canada, Hong Kong, and also has a network of distributors in 30 other countries.

Hexacath, 4, Passage St Antoine, 92508 Rueil-Malmaison, France

Tel : 00 33 1 41 39 01 90 – Fax : 00 33 1 41 39 01 93

Website :www.hexacath.com